Complement system is activated in stenotic aortic valves



      To examine the role of the complement system, a source of powerful proinflammatory mediators, in aortic valve stenosis (AS).

      Methods and Results

      Stenotic aortic valves (n = 24) were obtained at valve replacement surgery, and non-stenotic (n = 12) and early sclerotic (n = 4) valves at cardiac transplantations. The terminal complement complex C5b-9 was stained by immunohistochemistry. Expression of the anaphylatoxin receptors C3aR and C5aR was studied in the valves by immunohistochemistry and RT-PCR, and in isolated valve myofibroblats after stimulation with potential AS-accelerating factors (TNF-α and cigarette smoke) by RT-PCR. Cultured myofibroblasts were exposed to C3a, and their secretion of proinflammatory cytokines was assessed by ELISA.
      C5b-9 was found already in early aortic valve lesions, and its deposition was augmented in advanced stenotic valves. In stenotic valves, expression of C3aR mRNA was upregulated (p < 0.05) and strong staining of C3aR and C5aR was detected. Myofibroblasts in stenotic, but not in control valves, expressed C3aR, and, in isolated myofibroblasts, TNF-α and cigarette smoke induced C3aR mRNA expression (p < 0.05 for both). Stimulation of myofibroblasts with C3a resulted in enhanced secretion of MCP-1 (p < 0.001), IL-6 (p = 0.003), and IL-8 (p = 0.03).


      In stenotic aortic valves, complement is activated leading to generation of the anaphylatoxins C3a and C5a. Upregulation of C3aR in the valves as a result of inflammation and external risk factors, such as cigarette smoke, leads to an inflammatory response in aortic valve myofibroblasts. Complement activation in stenotic valves emerges as a novel pathogenic component of AS and may serve as a therapeutic target in this disease.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lindroos M.
        • Kupari M.
        • Valvanne J.
        • et al.
        Factors associated with calcific aortic valve degeneration in the elderly.
        Eur Heart J. 1994; 15: 865-870
        • Olsson M.
        • Thyberg J.
        • Nilsson J.
        Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves.
        Arterioscler Thromb Vasc Biol. 1999; 19: 1218-1222
        • O’Brien K.D.
        • Reichenbach D.D.
        • Marcovina S.M.
        • et al.
        Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of ‘degenerative’ valvular aortic stenosis.
        Arterioscler Thromb Vasc Biol. 1996; 16: 523-532
        • Mohler III, E.R.
        • Gannon F.
        • Reynolds C.
        • et al.
        Bone formation and inflammation in cardiac valves.
        Circulation. 2001; 103: 1522-1528
        • Otto C.M.
        • Kuusisto J.
        • Reichenbach D.D.
        • et al.
        Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies.
        Circulation. 1994; 90: 844-853
        • Olsson M.
        • Dalsgaard C.J.
        • Haegerstrand A.
        • et al.
        Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves.
        J Am Coll Cardiol. 1994; 23: 1162-1170
        • Helske S.
        • Lindstedt K.A.
        • Laine M.
        • et al.
        Induction of local angiotensin II-producing systems in stenotic aortic valves.
        J Am Coll Cardiol. 2004; 44: 1859-1866
        • Oksjoki R.
        • Kovanen P.T.
        • Pentikainen M.O.
        Role of complement activation in atherosclerosis.
        Curr Opin Lipidol. 2003; 14: 477-482
        • Niculescu F.
        • Rus H.
        Complement activation and atherosclerosis.
        Mol Immunol. 1999; 36: 949-955
        • Vlaicu R.
        • Niculescu F.
        • Rus H.G.
        • et al.
        Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque.
        Atherosclerosis. 1985; 57: 163-177
        • Laine P.
        • Pentikainen M.O.
        • Wurzner R.
        • et al.
        Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction.
        Am J Cardiol. 2002; 90: 404-408
      1. Oksjoki R, Jarva H, Kovanen PT, et al. Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions. Implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol 2003.

        • Siegel J.
        • Rent R.
        • Gewurz H.
        Interactions of C-reactive protein with the complement system I. Protamine-induced consumption of complement in acute phase sera.
        J Exp Med. 1974; 140: 631-647
        • Bhakdi S.
        Complement and atherogenesis: the unknown connection.
        Ann Med. 1998; 30: 503-507
        • Fujita T.
        • Endo Y.
        • Nonaka M.
        Primitive complement system—recognition and activation.
        Mol Immunol. 2004; 41: 103-111
        • Nataf S.
        • Davoust N.
        • Ames R.S.
        • et al.
        Human T cells express the C5a receptor and are chemoattracted to C5a.
        J Immunol. 1999; 162: 4018-4023
        • Zwirner J.
        • Werfel T.
        • Wilken H.C.
        • et al.
        Anaphylatoxin C3a but not C3a(desArg) is a chemotaxin for the mouse macrophage cell line J774.
        Eur J Immunol. 1998; 28: 1570-1577
        • Hartmann K.
        • Henz B.M.
        • Kruger-Krasagakes S.
        • et al.
        C3a and C5a stimulate chemotaxis of human mast cells.
        Blood. 1997; 89: 2863-2870
        • Schulman E.S.
        • Post T.J.
        • Henson P.M.
        • et al.
        Differential effects of the complement peptides C5a and C5a des Arg on human basophil and lung mast cell histamine release.
        J Clin Invest. 1988; 81: 918-923
        • el-Lati S.G.
        • Dahinden C.A.
        • Church M.K.
        Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells.
        J Invest Dermatol. 1994; 102: 803-806
        • Takabayashi T.
        • Vannier E.
        • Burke J.F.
        • et al.
        Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells.
        J Infect Dis. 1998; 177: 1622-1628
        • Goodman M.G.
        • Chenoweth D.E.
        • Weigle W.O.
        Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors.
        J Exp Med. 1982; 156: 912-917
        • Ember J.A.
        • Sanderson S.D.
        • Hugli T.E.
        • et al.
        Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin.
        Am J Pathol. 1994; 144: 393-403
        • Albrecht E.A.
        • Chinnaiyan A.M.
        • Varambally S.
        • et al.
        C5a-induced gene expression in human umbilical vein endothelial cells.
        Am J Pathol. 2004; 164: 849-859
      2. Oksjoki R, Laine P, Helske S, et al. Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis 2007.

        • Helske S.
        • Syvaranta S.
        • Kupari M.
        • et al.
        Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves.
        Eur Heart J. 2006; 27: 1495-1504
        • Seifert P.S.
        • Hugo F.
        • Hansson G.K.
        • et al.
        Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits.
        Lab Invest. 1989; 60: 747-754
        • Torzewski J.
        • Oldroyd R.
        • Lachmann P.
        • et al.
        Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation.
        Arterioscler Thromb Vasc Biol. 1996; 16: 673-677
        • Nauta A.J.
        • Daha M.R.
        • Tijsma O.
        • et al.
        The membrane attack complex of complement induces caspase activation and apoptosis.
        Eur J Immunol. 2002; 32: 783-792
        • Niculescu F.
        • Badea T.
        • Rus H.
        Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase.
        Atherosclerosis. 1999; 142: 47-56
        • Kilgore K.S.
        • Schmid E.
        • Shanley T.P.
        • et al.
        Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation.
        Am J Pathol. 1997; 150: 2019-2031
        • Skowasch D.
        • Schrempf S.
        • Preusse C.J.
        • et al.
        Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins.
        Heart. 2006; 92: 495-498
        • Seifert P.S.
        • Hugo F.
        • Tranum-Jensen J.
        • et al.
        Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions.
        J Exp Med. 1990; 172: 547-557
        • Bhakdi S.
        • Dorweiler B.
        • Kirchmann R.
        • et al.
        On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety.
        J Exp Med. 1995; 182: 1959-1971
        • Fondard O.
        • Detaint D.
        • Iung B.
        • et al.
        Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors.
        Eur Heart J. 2005; 26: 1333-1341
        • Helske S.
        • Syvaranta S.
        • Lindstedt K.A.
        • et al.
        Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves.
        Arterioscler Thromb Vasc Biol. 2006; 26: 1791-1798
        • Saad A.F.
        • Virella G.
        • Chassereau C.
        • et al.
        OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages.
        J Lipid Res. 2006; 47: 1975-1983
        • Pinckard R.N.
        • Olson M.S.
        • Giclas P.C.
        • et al.
        Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction.
        J Clin Invest. 1975; 56: 740-750
        • Mevorach D.
        • Mascarenhas J.O.
        • Gershov D.
        • et al.
        Complement-dependent clearance of apoptotic cells by human macrophages.
        J Exp Med. 1998; 188: 2313-2320
        • Tanaka K.
        • Sata M.
        • Fukuda D.
        • et al.
        Age-associated aortic stenosis in apolipoprotein E-deficient mice.
        J Am Coll Cardiol. 2005; 46: 134-141
        • Kaden J.J.
        • Dempfle C.E.
        • Grobholz R.
        • et al.
        Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis.
        Cardiovasc Pathol. 2005; 14: 80-87
        • Stewart B.F.
        • Siscovick D.
        • Lind B.K.
        • et al.
        Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study.
        J Am Coll Cardiol. 1997; 29: 630-634
        • Geertinger P.
        • Sorensen H.
        Complement as a factor in arteriosclerosis.
        Acta Pathol Microbiol Scand [A]. 1970; 78: 284-288
        • Schmiedt W.
        • Kinscherf R.
        • Deigner H.P.
        • et al.
        Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits.
        Arterioscler Thromb Vasc Biol. 1998; 18: 1790-1795
        • Persson L.
        • Boren J.
        • Robertson A.K.
        • et al.
        Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E−/− low-density lipoprotein receptor−/− mice.
        Arterioscler Thromb Vasc Biol. 2004; 24: 1062-1067
        • Holland M.C.
        • Morikis D.
        • Lambris J.D.
        Synthetic small-molecule complement inhibitors.
        Curr Opin Investig Drugs. 2004; 5: 1164-1173
        • Novaro G.M.
        • Tiong I.Y.
        • Pearce G.L.
        • et al.
        Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
        Circulation. 2001; 104: 2205-2209
        • Shavelle D.M.
        • Takasu J.
        • Budoff M.J.
        • et al.
        HMG CoA reductase inhibitor (statin) and aortic valve calcium.
        Lancet. 2002; 359: 1125-1126
        • Rosenhek R.
        • Rader F.
        • Loho N.
        • et al.
        Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis.
        Circulation. 2004; 110: 1291-1295
        • Rajamannan N.M.
        • Otto C.M.
        Targeted therapy to prevent progression of calcific aortic stenosis.
        Circulation. 2004; 110: 1180-1182